Listed

Pliant Therapeutics, Inc.

PLRXNasdaqCIK 1746473HealthcareFiscal year ends Dec 31

Reports and events: 106 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

Pliant Therapeutics, Inc., Reports and events
FiledFormWhat it isAccession number
2023-10-0316:53 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001746473-23-000062
2023-09-2607:34 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-23-241849
2023-08-0916:09 ET10-QQuarterly reportPeriod 2023-06-300001746473-23-000053
2023-08-0916:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-23-000051
2023-06-0816:46 ET8-K5.07 Shareholder vote results0001746473-23-000036
2023-05-0916:14 ET10-QQuarterly reportPeriod 2023-03-310001746473-23-000031
2023-05-0916:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-23-000029
2023-05-0106:08 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-23-128616
2023-04-2616:01 ETDEF 14AProxy statement0001746473-23-000012
2023-03-0916:13 ET10-KAnnual reportPeriod 2022-12-310001746473-23-000008
2023-03-0916:11 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-23-000007
2023-03-0816:22 ET8-K5.02 Departure or appointment of officers or directors0001193125-23-064549
2023-02-2316:07 ET8-K1.02 Termination of a material agreement0001193125-23-046525
2023-01-2517:26 ET8-K2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-23-015276
2023-01-2316:21 ET8-K8.01 Other events0001193125-23-013173
2023-01-2307:30 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-23-012607
2023-01-0908:31 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-23-004216
2022-11-1816:50 ET8-K5.02 Departure or appointment of officers or directors0001193125-22-289077
2022-11-0816:15 ET10-QQuarterly reportPeriod 2022-09-300001746473-22-000031
2022-11-0816:05 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-22-000030
2022-09-1616:06 ET8-K5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001193125-22-246364
2022-08-0816:11 ET10-QQuarterly reportPeriod 2022-06-300001746473-22-000027
2022-08-0816:08 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-22-000025
2022-07-1416:03 ET8-K2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-22-193726
2022-07-1107:00 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-22-190873
2022-06-1716:01 ET8-K5.07 Shareholder vote results0001193125-22-176473
2022-05-2717:01 ET10-K/AAnnual report, amendedPeriod 2021-12-310001193125-22-162455
2022-05-0916:18 ET10-QQuarterly reportPeriod 2022-03-310001746473-22-000021
2022-05-0916:11 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-22-000019
2022-05-0516:30 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001193125-22-142365
2022-04-2906:05 ETDEF 14AProxy statementPeriod 2022-06-160001140361-22-016716
2022-03-0117:26 ET10-K/AAnnual report, amendedPeriod 2021-12-310001193125-22-061695
2022-03-0121:33 ET8-K/A2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-22-000012
2022-03-0118:29 ET10-KAnnual reportPeriod 2021-12-310001746473-22-000010
2022-02-2816:07 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-22-000009
2022-01-1008:53 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001140361-22-001029
2021-11-0916:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-21-000025
2021-11-0916:10 ET10-QQuarterly reportPeriod 2021-09-300001746473-21-000023
2021-09-0707:31 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-21-266016
2021-08-0916:21 ET10-QQuarterly reportPeriod 2021-06-300001746473-21-000019
2021-08-0916:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-21-000017
2021-07-0210:17 ET8-K5.02 Departure or appointment of officers or directors0001746473-21-000011
2021-05-1017:16 ET10-QQuarterly reportPeriod 2021-03-310001746473-21-000008
2021-05-1016:49 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001746473-21-000005
2021-04-3015:37 ETDEF 14AProxy statementPeriod 2021-06-290001140361-21-015256
2021-03-1616:25 ET10-KAnnual reportPeriod 2020-12-310001564590-21-013589
2021-03-1616:15 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001564590-21-013576
2021-01-1317:08 ET8-K5.02 Departure or appointment of officers or directors0001193125-21-008213
2020-12-2106:05 ET8-K5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001193125-20-322128
2020-11-1016:22 ET10-QQuarterly reportPeriod 2020-09-300001564590-20-052990

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Nov 13, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.